Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New MAbs described by Oxford BioTherapeutics

Feb. 1, 2013

Encouraging results from phase III study of obinutuzumab in CLL

Jan. 31, 2013

FDA clears IND application for ICT-140

Jan. 30, 2013

OncoPep begins phase I/IIa trial of multipeptide vaccine in smoldering multiple myeloma

Jan. 30, 2013

Algeta begins research program on epratuzumab-based targeted thorium conjugate

Jan. 30, 2013

Chugai seeks Japanese approval of trastuzumab emtansine

Jan. 29, 2013

Interim data presented for FG-3019 in patients with PDAC

Jan. 29, 2013

OncoTherapy Science expands gastric cancer study of OTSGC-A24

Jan. 28, 2013

Findings from phase II/III study of Anyara in renal cell carcinoma presented

Jan. 28, 2013

Seattle Genetics and Millennium begin phase III trial of Adcetris

Jan. 28, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...